Committee ADAPP. 11. Chronic kidney disease and risk management: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S219–30.

Google Scholar 

Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.

Article  CAS  PubMed  Google Scholar 

Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–8.

Article  CAS  PubMed  Google Scholar 

Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–17.

Article  CAS  PubMed  Google Scholar 

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21.

Article  CAS  PubMed  Google Scholar 

Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–32.

Article  CAS  PubMed  Google Scholar 

Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50.

Article  CAS  PubMed  Google Scholar 

Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–51.

Article  CAS  PubMed  Google Scholar 

Yabe D, Hamamoto Y, Kawanami D, et al. A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses. J Diabetes Investig. 2025;16(10):1794–807.

Article  PubMed  PubMed Central  Google Scholar 

Furusawa S, Nomoto H, Oba-Yamamoto C, et al. Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study). Endocr J. 2024;71(6):603–16.

Article  CAS  PubMed  Google Scholar 

Moreno-Pérez O, Reyes-Garcia R, Guillen-Morote C, et al. Effects of oral semaglutide on kidney outcomes in people with type 2 diabetes: a nationwide, multicentre, retrospective, observational study (Renal_ENDO2S-RWD substudy). Clin Kidney J. 2025;18(8):sfaf227.

Article  PubMed  PubMed Central  Google Scholar 

Mima A, Kidooka S, Nakamoto T, et al. Effects of oral semaglutide on renal function in diabetic kidney disease: a short-term clinical study. In Vivo. 2024;38(1):308–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.

Article  PubMed  PubMed Central  Google Scholar 

Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821–35.

Article  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transpl. 2013;48(3):452–8.

Article  CAS  Google Scholar 

Mann JFE, Marx N, Deanfield JE, et al. Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the soul randomized trial. Diabetes Care. 2026;49(2):257–65.

Article  PubMed  PubMed Central  Google Scholar 

Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579–89.

Article  CAS  PubMed  Google Scholar 

MacIsaac RJ, Trevella P, Ekinci EI. Glucagon-like peptide-1 receptor agonists and kidney outcomes. J Diabetes. 2024;16(10):e13609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen J, Cooper ME, Coughlan MT. Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists. Diabetes Metab. 2025;51(3):101641.

Article  CAS  PubMed  Google Scholar 

Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.

Article  CAS  PubMed  Google Scholar 

Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–31.

Article  CAS  PubMed  Google Scholar 

Lin R, Hsu CL, Shih MC, et al. Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2026;28(1):518–28.

Article  CAS  PubMed  Google Scholar 

Fishkin A, Rozenberg A, Schechter M, et al. Kidney outcomes with glucagon-like peptide-1 receptor agonists versus other glucose-lowering agents in people with type 2 diabetes: a systematic review and meta-analysis of real-world data. Diabetes Metab Res Rev. 2025;41(5):e70066.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of sustain 6 and leader. Circulation. 2022;145(8):575–85.

Article  CAS  PubMed  Google Scholar 

Marques Vidas M, López-Sánchez P, Sánchez-Briales P, et al. Efficacy and safety in a real-world study of the new oral formulation of semaglutide in patients with chronic kidney disease and type 2 diabetes mellitus. J Clin Med. 2024;13(17):5166.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mariam Z, Niazi SK. Glucagon-like peptide agonists: a prospective review. Endocrinol Diabetes Metab. 2024;7(1):e462.

Article  CAS  PubMed  Google Scholar 

Schechter M, Melzer Cohen C, Fishkin A, et al. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovasc Diabetol. 2023;22(1):126.

Article  CAS  PubMed  PubMed Central  Google Scholar